FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922097817> ?p ?o ?g. }

• W2922097817 endingPage "522" @default.
• W2922097817 startingPage "505" @default.
• W2922097817 abstract "Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate administration should be considered for fetal neuroprotection when women present at ≤33 + 6 weeks with imminent preterm birth, defined as a high likelihood of birth because of active labour with cervical dilatation ≥4cm, with or without preterm pre-labour rupture of membranes, and/or planned preterm birth for fetal or maternal indications. There are no other known fetal neuroprotective agents. Outcomes The outcomes measured are the incidence of cerebral palsy (CP) and neonatal death. Evidence Published literature was retrieved through searches of PubMed or Medline, CINAHL, and the Cochrane Library in December 2017, using appropriate controlled vocabulary and key words (magnesium sulphate, cerebral palsy, preterm birth). Results were restricted to systematic reviews, randomized controlled trials, and relevant observational studies. There were no date or language restrictions. Searches were updated on a regular basis and incorporated in the guideline to December 2017. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment–related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies. Values The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table1). Benefits, harms, and costs Antenatal magnesium sulphate for fetal neuroprotection reduces the risk of “death or CP” (relative risk [RR] 0.85; 95% confidence interval [CI] 0.74–0.98; 4 trials, 4446 infants), “death or moderate-severe CP” (RR 0.85; 95% CI 0.73–0.99; 3 trials, 4250 infants), “any CP” (RR 0.71; 95% CI 0.55–0.91; 4, trials, 4446 infants), “moderate-to-severe CP” (RR 0.60; 95% CI 0.43–0.84; 3 trials, 4250 infants), and “substantial gross motor dysfunction” (inability to walk without assistance) (RR 0.60; 95% CI 0.43–0.83; 3 trials, 4287 women) at 2years of age. Results were consistent between trials and across the meta-analyses. There is no anticipated significant increase in health care–related costs because women eligible to receive antenatal magnesium sulphate will be judged to have imminent preterm birth. Validation Australian National Clinical Practice Guidelines were published in March 2010 by the Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate was recommended for fetal neuroprotection in the same dosage as recommended in these guidelines. However, magnesium sulphate was recommended only at <30 weeks gestation, based on 2 considerations. First, no single gestational age subgroup was considered to show a clear benefit. Second, in the face of uncertainty, the committee felt it was prudent to limit the impact of their clinical practice guidelines on resource allocation. In March 2010, the American College of Obstetricians and Gynecologists issued a Committee Opinion on magnesium sulphate for fetal neuroprotection. It stated that “the available evidence suggests that magnesium sulfate given before anticipated early preterm birth reduces the risk of cerebral palsy in surviving infants.” No official opinion was given on a gestational age cut-off, but it was recommended that physicians develop specific guidelines around the issues of inclusion criteria, dosage, concurrent tocolysis, and monitoring in accordance with 1 of the larger trials. Similarly, the World Health Organization also strongly recommends use of magnesium sulphate for fetal neuroprotection in its 2015 recommendations on interventions to improve preterm birth outcomes but cites further researching on dosing regimen and re-treatment. Sponsors Canadian Institutes of Health Research (CIHR). Summary Statement 1“Imminent preterm birth” is defined as a high likelihood of birth due to 1 or both of the following conditions (II-2): •Active labour with ≥4cm of cervical dilation, with or without preterm pre-labour rupture of membranes. •Planned preterm birth for fetal or maternal indications. Recommendations 1For women with imminent preterm birth (≤33 + 6 weeks), antenatal magnesium sulphate administration should be considered for fetal neuroprotection (I-A). 2Although there is controversy about upper gestational age, antenatal magnesium sulphate for fetal neuroprotection should be considered from viability to ≤33 + 6 weeks (II-1B). 3If antenatal magnesium sulphate has been started for fetal neuroprotection based on a clinical diagnosis of imminent preterm birth, tocolysis is no longer indicated and should be discontinued (III-A). 4Magnesium sulphate should be discontinued if delivery is no longer imminent or a maximum of 24hours of therapy has been administered (II-2B). 5For women with imminent preterm birth, antenatal magnesium sulphate for fetal neuroprotection should be administered as a 4-g intravenous loading dose, over 30 minutes, with or without a 1g per hour maintenance infusion until birth (II-2B). 6For planned preterm birth for fetal or maternal indications, magnesium sulphate should be started, ideally within 4hours before birth, as a 4-g intravenous loading dose, over 30 minutes (II-2B). 7There is insufficient evidence that a repeat course of antenatal magnesium sulphate for fetal neuroprotection should be administered (III-L). 8Delivery should not be delayed in order to administer antenatal magnesium sulphate for fetal neuroprotection if there are maternal and/or fetal indications for emergency delivery (III-E). 9When magnesium sulphate is given for fetal neuroprotection, maternity care providers should use existing protocols to monitor women who are receiving magnesium sulphate for preeclampsia/eclampsia (III-A). 10Indications for fetal heart rate monitoring in women receiving antenatal magnesium sulphate for neuroprotection should follow the fetal surveillance recommendations of the Society of Obstetricians and Gynaecologists of Canada 2007 Fetal Health Surveillance: Antepartum and Intrapartum Consensus Guideline (III-A). 11Decisions about neonatal resuscitation should not be influenced by whether or not the other received magnesium sulphate for fetal neuroprotection (II-I B)." @default.
• W2922097817 created "2019-03-22" @default.
• W2922097817 creator A5060277637 @default.
• W2922097817 creator A5077769927 @default.
• W2922097817 creator A5078749346 @default.
• W2922097817 creator A5079192303 @default.
• W2922097817 creator A5090770877 @default.
• W2922097817 date "2019-04-01" @default.
• W2922097817 modified "2023-10-18" @default.
• W2922097817 title "No. 376-Magnesium Sulphate for Fetal Neuroprotection" @default.
• W2922097817 cites W1533674302 @default.
• W2922097817 cites W1558801662 @default.
• W2922097817 cites W1573644537 @default.
• W2922097817 cites W1710815287 @default.
• W2922097817 cites W1953108956 @default.
• W2922097817 cites W1962502935 @default.
• W2922097817 cites W1967515370 @default.
• W2922097817 cites W1969847449 @default.
• W2922097817 cites W1972838992 @default.
• W2922097817 cites W1974941509 @default.
• W2922097817 cites W1981934276 @default.
• W2922097817 cites W1983967119 @default.
• W2922097817 cites W1987365105 @default.
• W2922097817 cites W1989389414 @default.
• W2922097817 cites W2000126618 @default.
• W2922097817 cites W2009242844 @default.
• W2922097817 cites W2011279249 @default.
• W2922097817 cites W2016988939 @default.
• W2922097817 cites W2017177908 @default.
• W2922097817 cites W2018816548 @default.
• W2922097817 cites W2031030759 @default.
• W2922097817 cites W2033447709 @default.
• W2922097817 cites W2034342856 @default.
• W2922097817 cites W2035420731 @default.
• W2922097817 cites W2037030847 @default.
• W2922097817 cites W2038328181 @default.
• W2922097817 cites W2049107611 @default.
• W2922097817 cites W2054131864 @default.
• W2922097817 cites W2058338213 @default.
• W2922097817 cites W2061602313 @default.
• W2922097817 cites W2069390816 @default.
• W2922097817 cites W2072033213 @default.
• W2922097817 cites W2093992438 @default.
• W2922097817 cites W2105345731 @default.
• W2922097817 cites W2122596654 @default.
• W2922097817 cites W2125927540 @default.
• W2922097817 cites W2126675210 @default.
• W2922097817 cites W2127766074 @default.
• W2922097817 cites W2138652400 @default.
• W2922097817 cites W2139772421 @default.
• W2922097817 cites W2169662692 @default.
• W2922097817 cites W2170365459 @default.
• W2922097817 cites W2188227032 @default.
• W2922097817 cites W2218431180 @default.
• W2922097817 cites W2231674867 @default.
• W2922097817 cites W2288458832 @default.
• W2922097817 cites W2300801594 @default.
• W2922097817 cites W2329223567 @default.
• W2922097817 cites W2335746834 @default.
• W2922097817 cites W2385241259 @default.
• W2922097817 cites W2556579141 @default.
• W2922097817 cites W2616116784 @default.
• W2922097817 cites W2736255997 @default.
• W2922097817 cites W2761276975 @default.
• W2922097817 cites W2763527823 @default.
• W2922097817 cites W2783185864 @default.
• W2922097817 cites W2986459372 @default.
• W2922097817 cites W4233092423 @default.
• W2922097817 cites W4251038397 @default.
• W2922097817 cites W4376595469 @default.
• W2922097817 doi "https://doi.org/10.1016/j.jogc.2018.09.018" @default.
• W2922097817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30879485" @default.
• W2922097817 hasPublicationYear "2019" @default.
• W2922097817 type Work @default.
• W2922097817 sameAs 2922097817 @default.
• W2922097817 citedByCount "35" @default.
• W2922097817 countsByYear W29220978172019 @default.
• W2922097817 countsByYear W29220978172020 @default.
• W2922097817 countsByYear W29220978172021 @default.
• W2922097817 countsByYear W29220978172022 @default.
• W2922097817 countsByYear W29220978172023 @default.
• W2922097817 crossrefType "journal-article" @default.
• W2922097817 hasAuthorship W2922097817A5060277637 @default.
• W2922097817 hasAuthorship W2922097817A5077769927 @default.
• W2922097817 hasAuthorship W2922097817A5078749346 @default.
• W2922097817 hasAuthorship W2922097817A5079192303 @default.
• W2922097817 hasAuthorship W2922097817A5090770877 @default.
• W2922097817 hasConcept C126322002 @default.
• W2922097817 hasConcept C131872663 @default.
• W2922097817 hasConcept C141071460 @default.
• W2922097817 hasConcept C142724271 @default.
• W2922097817 hasConcept C168563851 @default.
• W2922097817 hasConcept C17744445 @default.
• W2922097817 hasConcept C177713679 @default.
• W2922097817 hasConcept C1862650 @default.
• W2922097817 hasConcept C187212893 @default.
• W2922097817 hasConcept C189708586 @default.
• W2922097817 hasConcept C199539241 @default.

• next